MARKET

RNA

RNA

Atrium Therapeutics, Inc
NASDAQ
7.53
-0.43
-5.40%
Opening 13:47 11/12 EST
OPEN
7.89
PREV CLOSE
7.96
HIGH
7.89
LOW
7.52
VOLUME
153.25K
TURNOVER
--
52 WEEK HIGH
16.77
52 WEEK LOW
7.49
MARKET CAP
128.81M
P/E (TTM)
-1.9534
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNA last week (1102-1106)?
Weekly Report · 3d ago
Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy
Benzinga · 11/02 11:35
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
PR Newswire · 11/02 11:30
Weekly Report: what happened at RNA last week (1026-1030)?
Weekly Report · 11/02 10:31
Atrium Therapeutics Price Target Cut to $20.00/Share From $25.00 by HC Wainwright & Co.
Dow Jones · 10/28 11:52
Atrium Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 10/28 11:52
HC Wainwright & Co. Maintains Buy on Atrium Therapeutics, Lowers Price Target to $20
Benzinga · 10/28 11:42
Atrium Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
TipRanks · 10/28 10:16
More
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.

Webull offers Atrium Therapeutics Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.